[suPAR]

suPAR monograph

June 2021

Content:

suPAR – executive summary

The biomarker suPAR (soluble urokinase Plasminogen Activator Receptor) is the soluble form of the cell membrane-bound protein uPAR, expressed mainly on immune cells, endothelial cells, and smooth muscle cells. uPAR is released during inflammation or immune activation, and the suPAR level reflects the extent of immune activation in the individual[1]. All human beings have a baseline level of suPAR that is individually determined and increases with age.

The suPAR level is associated with morbidity and mortality in several acute and chronic diseases and in the general population[2-15]. The suPAR level is elevated across diseases and not solely associated with one specific disease. Therefore, suPAR is applicable as a prognostic marker and not as a diagnostic marker. This characteristic may be utilised for risk stratification in unselected patients.

In acute medical patients, a suPAR level below 4 ng/mL indicates a good prognosis and is supportive of discharge. In contrast, patients presenting with a suPAR level above 6 ng/mL have a high risk of a negative outcome, such as respiratory failure in COVID-19 patients and mortality

The suPAR blood level is stable with no diurnal variation and no changes following fasting. suPAR can be measured in blood, plasma, urine, cerebrospinal fluid, ascites fluid, and pleural fluid. The level increases and decreases with progression and improvement of a disease, respectively, but more slowly compared to, e.g. C-reactive protein (CRP).

In the general population the suPAR plasma level is 2-3 ng/mL in healthy individuals, about 3-4 ng/mL in unselected patients in emergency departments, and about 9-10 ng/mL in critically ill patients.

For further information, please see appendices and subsequent sections

suPAR in the general population

The following factors are associated with an **elevated suPAR level:**

- Daily smoking[1–5]
- Obesity[3]
- Previous AMI[3]
- Low HDL cholesterol/high LDL cholesterol[1–3]
- Unhealthy diet[3, 9]
- Physical inactivity[3]
- Age[1–3,5,6]

Moreover, an elevated suPAR level is associated with the **future** incidence of:

- Mortality[1]
- Cardiovascular diseases[1,2,8]
- Cancer[1,5]
- Type 2 diabetes[1]
  Renal failure[7]

  Finally, a change towards a healthier lifestyle is associated with a suPAR decrease – and the resultant suPAR is predictive of outcome (mortality). Hence, suPAR is not a death sentence – it is an early warning signal[8]

In the general population, the suPAR level is higher in **females** than in males; the suPAR levels in young, healthy males and females are about 2.5 ng/mL and 3.0 ng/mL, respectively. The suPAR level increases slightly with **age,** but, above all, it is affected by **lifestyle and risk factors**. Among lifestyle factors, **smoking** is definitely the most critical – daily smoking is associated with an increase in suPAR of 1-1.5 ng/mL compared to non-smokers[1–5,7,8].

Moreover, an **unhealthy diet**[9] and, to a lesser extent, **physical inactivity** may also increase the suPAR level[3]. However, the impact on the suPAR level is significantly smaller compared to the effect of smoking (about 0.2 ng/mL for an unhealthy diet). The association between alcohol consumption and suPAR is not clear[2,3,5], but the alcoholic liver disease causes very high suPAR levels[7].

Cardiovascular risk factors affect the suPAR level, as there is a slightly positive association with LDL-cholesterol and a clearly negative association with HDL-cholesterol[1–3]. **Previous AMI** causes an increase in suPAR level of about 0.4 ng/mL[3,7]. Two studies have demonstrated an association between elevated blood pressure and suPAR[1,2], but in a third study, this could not be confirmed[3]. A BMI of 20-35 kg/m^2 has no notable effect on the suPAR level, but in **severe obesity** (BMI > 40), the suPAR level is about 0.5 ng/mL higher than in normal-weight individuals[3].

suPAR and future development of diseases

In the general population, an elevated suPAR level is associated with future **development of cancer, cardiovascular diseases,** and **type 2 diabetes** and is a predictor of **premature mortality** and **renal failure** (**Figure 1**)[1,2,5,7].

Excitingly, data from the Danish Inter99 cohort show that the mortality risk is associated with the suPAR level itself not with the underlying risk factors that cause increased suPAR levels[8]. For example, the mortality risk in non-smokers with a high suPAR level is increased compared to smokers with a low suPAR level. Thus, learning about the individual's risk factors may indicate the reason for an elevated suPAR level. However, it still seems that the individual's risk is primarily correlated with the suPAR level.


Figure 1. *The left graph displays cancer incidence during a 12.6-year follow-up of 2,602 individuals in the Danish MONICA cohort. The suPAR level is below 3.4 ng/mL in the 1st quartile and above 4.9 ng/mL in the 4th quartile. **The right graph** displays mortality in the 1,310 males in the same study. The suPAR level is below 3.1 ng/mL in the 1st quartile and above 4.7 ng/mL in the 4th quartile. Figure modified from Eugen-Olsen et al., JIM 2010.*

The overall impact of lifestyle and risk factors on suPAR

Please note that although the single factors mentioned above, in general, have a minimal impact on suPAR, the **overall impact** of several risk factors may be considerable. Adjusted analyses show that a 30-year-old non-smoking and physically active male of normal weight on a healthy diet has a suPAR level of about 2.5 ng/mL, whereas a 30-year-old obese, heavily smoking, and inactive male on an unhealthy diet has a suPAR level of about 5.4 ng/mL[3]. This

exceeds the difference between the 1st and 4th suPAR quartile in Figure 1 and therefore indicates a considerable risk difference.

A change towards healthier lifestyle reduce suPAR and the resultant suPAR predict mortality

1. Eugen-Olsen, J. *et al.* Circulating soluble urokinase plasminogen activator receptor predicts cancer, cardiovascular disease, diabetes and mortality in the general population. *J. Intern. Med.* 268, 296–308 (2010).
2. Borné, Y., Persson, M., Melander, O., Smith, J. G. & Engström, G. Increased plasma level of soluble urokinase plasminogen activator receptor is associated with incidence of heart failure but not atrial fibrillation. *Eur. J. Heart Fail.* 16, 377–383 (2014).
3. Haupt, T. H. *et al.* Risk factors associated with serum levels of the inflammatory biomarker soluble urokinase plasminogen activator receptor in a general population. *Biomark. Insights* 9, 91–100 (2014).
4. Persson, M., Engström, G., Björkbacka, H. & Hedblad, B. Soluble urokinase plasminogen activator receptor in plasma is associated with incidence of CVD. Results from the Malmö Diet and Cancer Study. *Atherosclerosis* 220, 502–505 (2012).
5. Langkilde, A. *et al.* Increased plasma soluble uPAR level is a risk marker of respiratory cancer in initially cancer-free individuals. *Cancer Epidemiol. Biomark. Prev. Publ. Am. Assoc. Cancer Res. Cosponsored Am. Soc. Prev. Oncol.* 20, 609–618 (2011).
6. Persson, M., Engström, G., Björkbacka, H. & Hedblad, B. Soluble urokinase plasminogen activator receptor in plasma is associated with incidence of CVD. Results from the Malmö Diet and Cancer Study. *Atherosclerosis* 220, 502–505 (2012).
7. Hayek, S. S. *et al.* Soluble Urokinase Receptor and Chronic Kidney Disease. *N. Engl. J. Med.* 373, 1916–1925 (2015).
8. Haupt TH et al. Healthy lifestyles reduce suPAR and mortality in a Danish general population study. Immun Ageing. 2019 Jan 22;16:1.
9. Törnkvist PBS et al. Soluble urokinase plasminogen activator receptor is linearly associated with dietary quality and predicts mortality. Br J Nutr. 2019;121(6):699-708.

suPAR in the emergency department

In the emergency departments, shortened hospital stays and fewer beds cause a large patient turnover. For optimal treatment and observation of patients admitted to the emergency departments, a proper risk assessment is needed to ensure that the most ill patients are prioritised and are quickly examined and put under more careful observation. Moreover, unnecessary admissions and the complications from these (functional decline, delirium, and iatrogenic infections) are avoided by identifying those patients who can be discharged.

So far, systematised triage systems are used for this risk assessment and to prioritise the order of patients to be treated.

A significant proportion of patients admitted to the emergency departments are elderly medical patients. These patients are often, frail and multimorbid patients presenting unspecific symptoms.

Studies from various emergency departments located in the Copenhagen region, Denmark, have shown that suPAR is associated with:

- Age[1,2]
- Severe and/or multiple comorbidities[1,2]
- Length of hospital stay[2]
- Admission to the intensive care unit[2,3]
- Readmission within 30 and 90 days[2]
- 48-hour, 30-day and 90-day mortality[2]

This means that in **acute medical patients,** suPAR measured on admission is higher in **elderly** patients, patients who end up being **admitted for a long period**, patients ending up in the **intensive care unit**, **seriously or chronically ill** patients, and **multimorbid** patients

as well as patients who are readmitted or die within 30 as well as 90 days[1–4].

Even taking into account other well-known prognostic factors, including sex, age, Charlson score, and CRP, suPAR remains an <u>independent</u> predictor of readmission and mortality within 30 as well as 90 days[2].

On the other hand, **patients with a low suPAR level** are at a lower risk of being readmitted or dying than others of the same age.

Example:

- The background 30- and 90-day mortality in patients below the age of 70 is 1.5% and 2.9%, respectively.
- In a patient below the age of 70 with a suPAR level of **0-3 ng/mL,** the risk of dying within 30 and 90 days is 0.3% and 0.8%, respectively.
- By comparison, in a patient below the age of 70 with a suPAR level **above 9 ng/mL,** the risk of dying within 30 and 90 days is 19.7% and 27.6%, respectively[2].

Diagnoses

The suPAR level is elevated in emergency medical patients with:

- Infectious diseases including COVID-19, cancer, diabetes, dementia, paralyses, cardiovascular diseases, chronic pulmonary diseases, peptic ulcer, hepatic diseases, rheumatic diseases, and renal/urinary tract diseases[1,2,4].

Data from Hvidovre Hospital emergency department[2].

Age: Median (25-75%) suPAR level:
- 0-50 years: 2.3 ng/mL (1.8-3.0)
- 50-70 years: 3.0 ng/mL (2.3-4.2)

- >70 years: 4.4 ng/mL (3.2-6.1)

Length of hospital stay: Median suPAR level (25-75%):
- 0 days: 2.6 ng/mL (1.9-3.6)
- 2-4 days: 3.7 ng/mL (2.7-5.3)
- >10 days: 5.1 ng/mL (3.6-7.5)

Admission to intensive care unit:
Median suPAR level (25-75%):
- ÷ intensive care unit: 3.2 ng/mL (2.2-4.6)
- + intensive care unit: 5.6 ng/mL (3.0-7.9)

Charlson score (number and severity of comorbidities):
Median suPAR level (25-75%):
- No comorbidities: 2.9 ng/mL (2.1-4.2)
- Charlson score = 1: 3.7 ng/mL (2.7-5.4)
- Charlson score ≥ 4: 7.2 ng/mL (4.8-10.9)

Readmission: Median suPAR level (25-75%):
- Neither readmission nor mortality within 30 days: 3.0 ng/mL (2.2-4.2)
- Readmission within 30 days: 3.9 ng/mL (2.7-5.6)

Mortality (see Appendix 1):
Median suPAR level (25-75%):
- Survived for 30 days: 3.1 ng/mL (2.2-4.5)
- Died within 30 days: 6.8 ng/mL (4.7-9.9)
- 30-day mortality AUC: 0.84 (95% CI: 0.81-0.86)

suPAR and clinical signs

suPAR is correlated with disease severity, but is suPAR correlated to the clinical signs? In a study published in Critical Care Medicine in

2018, the authors found that suPAR is correlated to the number of clinical signs (registered using the NEWS score). However, many patients with none or 1 clinical sign had high suPAR (Figure 2) and these patients (as illustrated with the red box) had a high risk of mortality[5]. Interestingly, suPAR was even stronger for those with none or few clinical signs compared to those presenting with multiple clinical signs, perhaps because these patients do not receive the same level of clinical attention[5].


Figure 2: suPAR levels according to NEWS score. N denotes the number of acute medical patients in each group. The red box illustrates that patients with 0-1 in NEWS score can have a high suPAR level[5].

suPAR in a randomised controlled trial (RCT)

An RCT including more than 16.000 acute medical patients showed that patients who had their **suPAR level measured** (suPAR group)

were **significantly more often discharged** within 24 hours of admittance than patients without suPAR levels measured (control group). Furthermore, the **mean length of hospital stay** in the suPAR group was **6,5 hours shorter** compared to the control group (p<0.05).[6]

Although significantly more patients were discharged within 24 hours, there was **no increased mortality** among these patients. In those discharged with measured suPAR, 30-day mortality was 1,3%, and in the control arm, it was 1,8% (p=0.08). The suPAR AUC for 30-day mortality among the patients discharged within 24 hours was 0.92.[7] Further analysis of the triage data showed that the Youden index was 5,9 ng/mL. Triaging patients down with suPAR below and up above the Youden index (5,9 ng/mL) resulted in 34% more patients triaged green (Figure 2).

Included N=4420	Standard triaging (%)	Triaging with suPAR (%)
Red category	251 (4.9)	369 (9.0)
Orange category	**1241 (28.5)**	**445 (10.1)**
Yellow category	1243 (28.1)	1267 (28.7)
Green category	1721 (38.9)	**2312 (52.3)**

Figure 3. Comparison of distribution of patients in triage groups between standard triage and triage with knowledge of suPAR. From Schultz et al., 2019.[7]

Clinical guidelines and cut-off values have been developed at Copenhagen University Hospital, Hvidovre in Denmark, where suPAR measurement was implemented as a clinical routine procedure in 2013 (Figure 4). The clinical guideline was recently shown to be applicable for not only acute patients but also for COVID-19 patients[8-11].


Figure 4: Guideline developed at Copenhagen University Hospital Hvidovre, Denmark.

1. Haupt, T H. *et al.* Plasma suPAR levels are associated with mortality, admission time, and Charlson Comorbidity Index in the acutely admitted medical patient: a prospective observational study. *Crit. Care* 16, R130 (2012).

2. Rasmussen, LJH. *et al.* Soluble urokinase plasminogen activator receptor (suPAR) in acute care: a strong marker of disease presence and severity, readmission and mortality. A retrospective cohort study Emerg Med J. 2016 Nov;33(11):769-775

3. Raggam, RB. *et al.* Soluble urokinase plasminogen activator receptor predicts mortality in patients with systemic inflammatory response syndrome. *J. Intern. Med.* 276, 651–8 (2014).

4. Nayak, RK., Allingstrup, M., Phanareth, K. & Kofoed-Enevoldsen, A. suPAR as a biomarker for risk of readmission and mortality in the acute medical setting. 62, 1–4 (2015).

5. Rasmussen LJH *et al.*, Combining National Early Warning Score With Soluble Urokinase Plasminogen Activator Receptor (suPAR) Improves Risk Prediction in Acute Medical Patients: A Registry-Based Cohort Study. Crit Care Med. 2018 Dec;46(12):1961-1968

6. Schultz M. *et al.* Availability of suPAR in emergency departments may improve risk stratification: a secondary analysis of the TRIAGE III trial. Scand J Trauma Resusc Emerg Med. 2019 Apr 11;27(1):43.

7. Schultz M. *et al.* "Early Discharge from the Emergency Department Based on Soluble Urokinase Plasminogen Activator Receptor (suPAR) Levels: A TRIAGE III Substudy. Disease Markers, vol. 2019, Article ID 3403549, 8 pages, 2019

8. Rovina N, Soluble urokinase plasminogen activator receptor (suPAR) as an early predictor of severe respiratory failure in patients with COVID-19 pneumonia. Crit Care. 2020 Apr 30;24(1):187. doi: 10.1186/s13054-020-02897-4.

9. Arnold DT et al. Predicting outcomes of COVID-19 from admission biomarkers: a prospective UK cohort stud.y Emerg Med J. 2021 May 21;emermed-2020-210380. doi: 10.1136/emermed-2020-210380.

10. Oulhaj A et al. Admission levels of Soluble Urokinase Plasminogen Activator Receptor (suPAR) are Associated with the Development of Severe Complications in Hospitalised COVID-19 Patients: A Prospective Cohort Study. Int J Infect Dis. 2021 Apr 20;107:188-194. doi: 10.1016/j.ijid.2021.04.026.

11. Azam et al. Soluble Urokinase Receptor (SuPAR) in COVID-19-Related AKI J Am Soc Nephrol. 2020 Nov;31(11):2725-2735. Clin Chem Lab Med. 2021 Jun 14

12. Stauning MA at al, Soluble Urokinase Plasminogen Activator Receptor as a Decision Marker for Early Discharge of Patients with COVID-19 Symptoms in the Emergency Department. J Emerg Med. 2021 Mar 26:S0736-4679(21)00295-X.

suPAR in infectious diseases

The suPAR level is elevated in patients with infectious diseases compared with healthy individuals. An elevated level is associated with:

- Advanced disease
- Poor prognosis

This applies to various infectious diseases, among others:

- HIV[1-5, 25]
- Sepsis[6-11]
- Hepatitis B[12]
- Hepatitis C[13-14]
- Tuberculosis[15-17]
- Malaria[18-19]
- Meningitis[21-22]
- Pneumonia[23-24]
- COVID-19

In general, the suPAR level is slightly elevated **in patients with infectious diseases.** In all infectious diseases studied, an elevated suPAR level is associated with a poorer prognosis. In infectious diseases, the diagnostic value of suPAR is weak, but instead, it has a prognostic value.

In patients with **HIV infection,** it was demonstrated that the suPAR level is slightly elevated and increases with the disease stage (WHO criteria). The first study of suPAR in HIV showed that suPAR was at least as strong a prognostic marker of the natural progression of HIV as CD4 and viral load[1]. Antiretroviral therapy (ART) causes a decrease in suPAR of about 17%[2]. However, after 5 years of treatment, the patients' suPAR level is still higher than in healthy

controls[2]. Side effects of treatment are associated with higher suPAR levels[3]. In addition to the correlation with virological and immunological effects of the infection, the suPAR level correlates with age, metabolic syndrome, smoking, and low muscle mass[4]. In HIV patients with ART-induced viral suppression, suPAR is a superior and independent predictor of non-AIDS events comorbidities (e.g. cardiovascular and renal diseases).

In patients with **sepsis**[5-7], it has been found that the suPAR level is of some diagnostic value, as it increases with seriousness of sepsis and is frequently above 10 ng/mL in patients with impaired organ function[8,9]. However, most studies show that CRP and procalcitonin (PCT) are better diagnostic markers of bacterial sepsis, whereas suPAR is the best prognostic marker[6,10]. In a later cohort, it was shown and validated that suPAR combined with the APACHE score can improve the risk stratification of patients with sepsis[11].

The suPAR level is elevated in **hepatitis B patients** with hepatic fibrosis compared to patients with no or mild fibrosis. Thus, suPAR may be useful for the identification of hepatitis B patients with significant fibrosis[12].

In **hepatitis C patients,** the suPAR level is elevated, and the level increases with the severity of fibrosis. Because hepatic disease and fibrosis affect the suPAR level, the prognostic value and the reflection of disease severity are probably a result of the liver condition rather than the hepatitis C infection[13]. This is supported by data demonstrating that suPAR is also associated with seriousness and prognosis in patients with non-alcoholic fatty liver disease[14].

Active tuberculosis (TB) causes a substantial increase in suPAR level, typically to about 6-7 ng/mL – the higher, the worse[15,16]. A study from Guinea-Bissau has shown that the suPAR level measured upon initiation of treatment for TB is a prognostic marker of mortality during treatment. Measurement of suPAR after one month of treatment

demonstrated that the change in suPAR level was also associated with mortality.Patients experiencing no decrease – or even an increase – in suPAR level have a poorer prognosis than patients experiencing a decrease following one month of treatment[17].

In **malaria**, suPAR has been studied in children, adults, and pregnant women. A doubling of the suPAR level is observed in children, which decreases back to a normal level following 14 days of effective treatment[18]. In adult patients with malaria and acute renal damage, suPAR was associated with the severity of the renal damage and was higher in patients who subsequently needed dialysis[19]. In pregnant women infected with malaria, an elevated suPAR level is associated with a low birth weight of the baby[20].

An elevated suPAR level in the cerebrospinal fluid (CSF) in children and adults with **meningitis** is associated with increased mortality[21,22].

In children with **pneumonia**, suPAR is associated with the severity of the infection and length of hospital stay[23]. In adults with sepsis and ventilator-associated pneumonia, the suPAR level is strongly and independently associated with a negative prognosis[24].

In **COVID-19**, an early elevation of suPAR, e.g. in patients that present with symptoms of SARS-CoV-2 infection in the Emergency Department, is associated with increased risk of severe COVID-19 development. Including respiratory failure, acute kidney injury, and mortality[26-29]. Clinical relevant cut-offs have been identified with a suPAR below 4 ng/ml indicating low risk of adverse outcomes and a suPAR above 6 ng/ml for high risk of negative outcome such as severe respiratory failure[26-29, Altintas et al., submitted].

An open-label randomised clinical trial (CORIMUNO-ANA-1) investigated the efficacy of Anakinra in addition to usual care for patients in hospital with COVID-19[30]. The study population consisted

of patients with a mild-to-moderate disease requiring low-flow supplemental oxygen, patients receiving further respiratory support were excluded. Notably, enrolment criteria did not include hyper inflammation .A CRP concentration of 25 mg/L or higher was required, However this threshold is not indicative of hyperinflammation, which is usually defined as greater than 100 mg/L.

Anakinra was administered intravenously at a dose of 400 mg per day for the first 3 days, followed by gradual tapering for 2 days before discontinuation. Corticosteroids were not an essential and standardised treatment in the usual care group, with administration instead being at physician discretion.
The study was stopped early by recommendation of the data safety monitoring board for futility on the basis of an interim analysis of the first 102 patients, after 116 patients had been randomly assigned to treatment (59 to the anakinra group and 57 to the usual care group), because no significant difference was found between the groups regarding the primary outcomes of 4-day improvement, 14-day ventilation requirement or mortality.

The main finding of this study was that treatment with Anakinra did not improve clinical outcomes in patients with mild-to-moderate COVID-19. In an accompanying editorial[31], the authors state that "as the field of IL-1 inhibition in COVID-19 moves forward, key questions still need addressing. The main challenge is to identify patients who might most benefit from treatment, either through correct timing of administration or through molecular taxonomy of individual inflammatory responses. Because IL-1α and IL-β are notoriously hard to measure in circulation, clinically useful biomarkers for patient selection include C-reactive protein, IL-6, ferritin (all proxies for IL-1 bioactivity),and the soluble urokinase plasminogen activator receptor"[30-31].

There are increasing data showing that suPAR is an early and strong indicator of COVID-19 progression. suPAR is strongly linked to early

innate immune activation, resulting in IL-1beta production, increasing the suPAR level. An early suPAR level of above 6 ng/mL indicates an immune activation on the road to hyperinflammation resulting in a dysfunctional and dysregulated immune system. This early triggering of immune activation is supported by laboratory findings[32] . In the "International Collaboration on Inflammation in COVID-19 (ISIC), the predictive role of biomarkers was tested across countries (USA, Greece, Denmark, and Germany), including 959 COVID-19 patients measured within 48-hours after presented at the Emergency Department. The study included the most promising biomarkers reported: CRP, Ferritin, Procalcitonin, D-dimer, IL-6, Lactate dehydrogenase (LDH), and suPAR[33]. In May 2021, the data presented at the AAC conference showed that the Area Under the Curve (AUC) for predicting the combined COVID-19 outcome (severe respiratory failure, dialysis, mortality) were as follows: suPAR had the highest AUC of 0.80 (95%CI[0.75-0.83]), followed by procalcitonin (0.75, 95%CI[0.71-0.78]), LDH (0.71, 95%CI[0.68-0.75]), and IL-6 (0.67, 95%CI[0.62-0.72]) [33]. That suPAR is the single strongest biomarker of COVID-19 progressing, even stronger than clinical scores was supported by an English study[27].

As a suPAR above 6 ng/mL is associated with a high risk of a negative outcome in COVID-19, suPAR may be the ideal candidate for early intervention and inhibiting the progression to hyper inflammation. The use of suPAR above 6 ng/mL will *exclude* patients with low suPAR levels with a good systemic immune response who may experience adverse or detrimental effects of immune intervention and *include* patients with elevated suPAR for whom intervention of hyper inflammation may be beneficial.

Indeed, this was the idea behind the SAVE[34] and SAVE MORE[35] studies. SAVE was an open-label suPAR guided Anakinra trial using a suPAR level above 6 ng/mL as inclusion criteria and compared the effect of Anakinra to comparators (COVID-19 patients matched for sex

and age with suPAR above 6 ng/ml) on top of standard of care (SoC) (most patients received Remdesivir and dexamethasone). The study showed a highly significant improvement in prognosis in those who received the Anakinra treatment. The SAVE MORE followed the same idea but was a double-blinded randomised controlled study including 37 hospitals in Italy and Greece. The SAVE MORE study showed a significant reduction in progression of almost 3-fold in those who received Anakinra (WHO 10-point COVID progression scale). The study screened 1060 COVID-patients early in infection (ICU patient was exclusion criteria), of whom 606 (57%) had suPAR above 6 ng/mL[35].

Regarding respiratory failure, 31.7% in the SoC and placebo arm developed respiratory failure versus 20.7% in the SoC and Anakinra arm. However, it should be noted that among the patients who had suPAR level *below* 6 ng/mL (N=454), only 2,8% developed respiratory failure (personal communication Evangelos J. Giamarellos-Bourboulis). This further substantiates the idea behind the trial that suPAR can identify those who may have a positive effect of Anakinra.

In conclusion, suPAR is an early and strong predictor of COVID-19 disease progression. Treating COVID-19 patients with suPAR above 6 ng/mL with IL-1 receptor antagonist Anakinra significantly reduces risk of progression to severe disease by almost 3-fold.

1. Sidenius N, Sier CF, Ullum H et al. Serum level of soluble urokinase-type plasminogen activator receptor is a strong and independent predictor of survival in human immunodeficiency virus infection. Blood 2000;96(13):4091-4095.
2. Ostrowski SR, Katzenstein TL, Pedersen M et al. Plasma levels of intact and cleaved urokinase receptor decrease in HIV-1-infected patients initiating highly active antiretroviral therapy. Scand J Immunol 2006;63(6):478-486.
3. Andersen O, Eugen-Olsen J, Kofoed K, Iversen J, Haugaard SB. Soluble urokinase plasminogen activator receptor is a marker of dysmetabolism in HIV-infected patients receiving highly active antiretroviral therapy. J Med Virol 2008;80(2):209-216.
4. Langkilde A, Petersen J, Klausen HH, Henriksen JH, Eugen-Olsen J, Andersen O. Inflammation in HIV-infected patients: impact of HIV, lifestyle, body composition, and demography - a cross sectional cohort study. PLoS One 2012;7(12):e51698.
5. Hoenigl M et al and the ACTG NWCS 411 study team. Soluble Urokinase Plasminogen Activator Receptor (suPAR) is predictive of Non-AIDS Events during Antiretroviral Therapy-mediated Viral Suppression. Clin Infect Dis. 2018 ciy966

6. Donadello K, Scolletta S, Covajes C, Vincent JL. suPAR as a prognostic biomarker in sepsis. BMC Med 2012;10:2. doi: 10.1186/1741-7015-10-2.:2-10.
7. Donadello K, Scolletta S, Taccone FS et al. Soluble urokinase-type plasminogen activator receptor as a prognostic biomarker in critically ill patients. J Crit Care 2014;29(1):144-149.
8. Koch A, Voigt S, Kruschinski C et al. Circulating soluble urokinase plasminogen activator receptor is stably elevated during the first week of treatment in the intensive care unit and predicts mortality in critically ill patients. Crit Care 2011;15(1):R63.
9. Suberviola B, Castellanos-Ortega A, Ruiz RA, Lopez-Hoyos M, Santibanez M. Hospital mortality prognostication in sepsis using the new biomarkers suPAR and proADM in a single determination on ICU admission. Intensive Care Med 2013;39(11):1945-1952.
10. Giamarellos-Bourboulis EJ, Georgitsi M. Host response biomarker in sepsis: suPAR detection. Methods Mol Biol 2015;1237:241-6. doi: 10.1007/978-1-4939-1776-1_18.:241-246.
11. Giamarellos-Bourboulis EJ, Norrby-Teglund A, Mylona V et al. Risk assessment in sepsis: a new prognostication rule by APACHE II score and serum soluble urokinase plasminogen activator receptor. Crit Care 2012;16(4):R149.
12. Sevgi DY, Bayraktar B, Gunduz A et al. Serum soluble urokinase-type plasminogen activator receptor and interferon-gamma-induced protein 10 levels correlate with significant fibrosis in chronic hepatitis B. Wien Klin Wochenschr 2015.
13. Berres ML, Schlosser B, Berg T, Trautwein C, Wasmuth HE. Soluble urokinase plasminogen activator receptor is associated with progressive liver fibrosis in hepatitis C infection. J Clin Gastroenterol 2012;46(4):334-338.
14. Sjowall C, Martinsson K, Cardell K, Ekstedt M, Kechagias S. Soluble urokinase plasminogen activator receptor levels are associated with severity of fibrosis in non-alcoholic fatty liver disease. Transl Res 2015;165(6):658-666.
15. Eugen-Olsen J, Gustafson P, Sidenius N et al. The serum level of soluble urokinase receptor is elevated in tuberculosis patients and predicts mortality during treatment: a community study from Guinea-Bissau. Int J Tuberc Lung Dis 2002;6(8):686-692.
16. Rabna P, Andersen A, Wejse C et al. High mortality risk among individuals assumed to be TB-negative can be predicted using a simple test. Trop Med Int Health 2009;14(9):986-994.
17. Rabna P, Andersen A, Wejse C et al. Utility of the plasma level of suPAR in monitoring risk of mortality during TB treatment. PLoS One 2012;7(8):e43933.
18. Perch M, Kofoed P, Fischer TK et al. Serum levels of soluble urokinase plasminogen activator receptor is associated with parasitemia in children with acute Plasmodium falciparum malaria infection. Parasite Immunol 2004;26(5):207-211.
19. Plewes K, Royakkers AA, Hanson J et al. Correlation of biomarkers for parasite burden and immune activation with acute kidney injury in severe falciparum malaria. Malar J 2014;13:91. doi: 10.1186/1475-2875-13-91.:91-13.
20. Ostrowski SR, Ullum H, Goka BQ et al. Plasma concentrations of soluble urokinase-type plasminogen activator receptor are increased in patients with malaria and are associated with a poor clinical or a fatal outcome. J Infect Dis 2005;191(8):1331-1341.
21. Tzanakaki G, Paparoupa M, Kyprianou M, Barbouni A, Eugen-Olsen J, Kourea-Kremastinou J. Elevated soluble urokinase receptor values in CSF, age and bacterial meningitis infection are independent and additive risk factors of fatal outcome. Eur J Clin Microbiol Infect Dis 2012;31(6):1157-1162.
22. Ostergaard C, Benfield T, Lundgren JD, Eugen-Olsen J. Soluble urokinase receptor is elevated in cerebrospinal fluid from patients with purulent meningitis and is associated with fatal outcome. Scand J Infect Dis 2004;36(1):14-19.
23. Wrotek A, Jackowska T. The role of the soluble urokinase plasminogen activator (suPAR) in children with pneumonia. Respir Physiol Neurobiol 2015;209:120-3. doi: 10.1016/j.resp.2014.12.018. Epub;%2015 Jan 17.:120-123.
24. Savva A, Raftogiannis M, Baziaka F et al. Soluble urokinase plasminogen activator receptor (suPAR) for assessment of disease severity in ventilator-associated pneumonia and sepsis. J Infect 2011;63(5):344-350.
25. Oliveira I, Andersen A, Furtado A et al. Assessment of simple risk markers for early mortality among HIV-infected patients in Guinea-Bissau: a cohort study. BMJ Open 2012;2(6):e001587.

26   Rovina N, Soluble urokinase plasminogen activator receptor (suPAR) as an early predictor of severe respiratory failure in patients with COVID-19 pneumonia. Crit Care. 2020 Apr 30;24(1):187. doi: 10.1186/s13054-020-02897-4.

27   Arnold DT et al. Predicting outcomes of COVID-19 from admission biomarkers: a prospective UK cohort study.   Emerg Med J. 2021 May 21;emermed-2020-210380. doi: 10.1136/emermed-2020-210380.

28   Oulhaj A et al. Admission levels of Soluble Urokinase Plasminogen Activator Receptor (suPAR) are Associated with the Development of Severe Complications in Hospitalised COVID-19 Patients: A Prospective Cohort Study. Int J Infect Dis. 2021 Apr 20;107:188-194. doi: 10.1016/j.ijid.2021.04.026.

29   Azam et al. Soluble Urokinase Receptor (SuPAR) in COVID-19-Related AKI J Am Soc Nephrol. 2020 Nov;31(11):2725-2735.

30   The CORIMUNO-19 Collaborative group Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia: a randomised controlled trial. Lancet Respir Med. 2021 doi: 10.1016/S2213-2600(20)30556-7

31   Cacalli G and Dagna L, The right place for IL-1 inhibition in COVID-19. Lancet Respir Med. Vol 9/3, p223-224

32   Renieris G et al, IL-1 Mediates Tissue Specific Inflammation and Severe Respiratory Failure In Covid-19: Clinical And Experimental Evidence. medRxiv 2021.04.09.21255190; doi: https://doi.org/10.1101/2021.04.09.21255190

33   Meloche C et al, Biomarkers of Inflammation and Outcomes of Patients sHospitalised for Covid-19: The International Study of Inflammation in Covid-19. Journal of the American College of Cardiology 77/18, Supplement 1, 11 May 2021, Page 3030

34   Kyriazopoulou E et al, An open label trial of anakinra to prevent respiratory failure in COVID-19. Elife 2021 Mar 8;10:e66125. doi: 10.7554/eLife.66125.

35   Kyriazopoulou E et al Early Anakinra Treatment for COVID-19 Guided by Urokinase Plasminogen   receptor redRxiv 2021.05.16.21257283; doi: https://doi.org/10.1101/2021.05.16.21257283

suPAR in cancer

The suPAR level is elevated in cancer patients compared to healthy individuals, and a high suPAR level is associated with:

- Advanced disease
- High TNM stage
- Aggressive and invasive tumor growth
- Metastatic disease
- Poor prognosis

This applies to various types of cancer, among others:

- Acute leukemia[1]
- Colorectal cancer[2–4]
- Hepatic cancer[5]
- Cervical cancer[6]
- Lung cancer (small cell and non-small cell)[7]
- Lymphomas[8]
- Ovarian cancer[9]
- Pancreatic cancer[10]
- Prostate cancer[11]
- Esophageal cancer[3]
- Gastric cancer[3,12]

Thus, various cancers cause an elevated plasma suPAR level. The more severe, and advanced disease, the higher the suPAR level. suPAR is therefore also a prognostic marker in cancer patients reflecting mortality. Cancer patients with a low suPAR level have a better chance of progression-free survival.

An elevated suPAR level is associated with an increased risk of lung cancer and other cancers in the general population. Among

smokers, the risk of lung cancer is also higher in individuals with an elevated suPAR level compared to those with lower suPAR levels[13].

In **prostate cancer** patients, the suPAR level is higher than in patients with benign prostatic hyperplasia[11].

In **neurologic patients** with paraneoplastic cerebellar syndromes or carcinomatous meningitis, the suPAR level is also elevated in plasma and cerebrospinal fluid[14].

In patients with **gastrointestinal cancers**, the suPAR level is higher in patients with esophageal cancer than patients with colorectal cancer[3].

suPAR in relation to cancer diagnostics and other biomarkers

An elevated suPAR level has proved to be an early predictor of future development of hepatocellular carcinoma in patients with liver diseases. The suPAR level may be elevated as early as 1-7 years before the appearance of imaging signs of hepatic cancer. In this study, suPAR was statistically stronger than alpha-fetoprotein[5].

In patients with **ovarian tumors**, a combination of suPAR and CA-125 can discriminate benign tumors from malignant tumors (AUC 0.94; 95% CI 0.90-0.98)[9].

suPAR in cancer treatment

In patients with resectable **colorectal cancer**, the suPAR level is lower than in patients with unresectable disease receiving palliative treatment[3,4]. Furthermore, suPAR might help guide preoperative treatment decisions regarding patients' outcomes and identify patients particularly susceptible to acute kidney injury[16].

In women with **cervical cancer**, the suPAR level decreases significantly following surgery[6].

In patients with **acute leukemia**, the suPAR plasma level correlates with the number of circulating tumor cells. Following treatment with chemotherapy, the suPAR level decreases to a normal level in parallel with a reduction in the number of tumor cells[1].

In patients without known cancer but with nonspecific severe symptoms and signs of cancer referred to a diagnostic outpatient clinic for an accelerated cancer diagnostic program, elevated suPAR levels were significantly associated with newly diagnosed cancer during follow-up[15]. Thus, a high suPAR level is associated with an increased risk of finding cancerpatients[15]. In cancer patients, elevated suPAR is associated with a poor prognosis and a shorter survival[4,10–12].

1. Mustjoki, S., Sidenius, N. & Sier, C. F. M. Soluble Urokinase Receptor Levels Correlate with Number of Circulating Tumor Cells in Acute Myeloid Leukemia and Decrease Rapidly during Chemotherapy Soluble Urokinase Receptor Levels Correlate with Number of Circulating Tumor Cells in Acute Myeloid Leuke. 7126–7132 (2000).

2. Lomholt, a F., Høyer-Hansen, G., Nielsen, H. J. & Christensen, I. J. Intact and cleaved forms of the urokinase receptor enhance discrimination of cancer from non-malignant conditions in patients presenting with symptoms related to colorectal cancer. *Br. J. Cancer* 101, 992–7 (2009).

3. Usnarska-Zubkiewicz, L., Strutyńska-Karpińska, M., Zubkiewicz-Kucharska, A., Zarębski, P. & Grabowski, K. Soluble Urokinase-Type Plasminogen Activator Receptor and Ferritin Concentration in Patients with Advanced Alimentary Tract Carcinoma. Relationship to Localisation, Surgical Treatment and the Stage of the Disease - Preliminary Report. *Adv. Clin. Exp. Med.* 23, 959–967 (2014).

4. Tarpgaard, L. S. *et al.* Intact and cleaved plasma soluble urokinase receptor in patients with metastatic colorectal cancer treated with oxaliplatin with or without cetuximab. *Int. J. Cancer* 1, n/a–n/a (2015).

5. Chounta, A. *et al.* Serum soluble urokinase plasminogen activator receptor as a screening test for the early diagnosis of hepatocellular carcinoma. *Liver Int.* 35, 601–607 (2015).

6. Jing, J. *et al.* Evaluating the value of uPAR of serum and tissue on patients with cervical cancer. *J. Clin. Lab. Anal.* 26, 16–21 (2012).

7. Cobos, E., Jumper, C. & Lox, C. Pretreatment Determination of the Serum Urokinase Plasminogen Activator and its Soluble Receptor in Advanced Small-Cell Lung Cancer or Non-Small-Cell Lung Cancer. *Clin. Appl. Thromb.* 9, 241–246 (2003).

8. Rubio-Jurado, B. *et al.* Circulating Levels of Urokinase-Type Plasminogen Activator Receptor and D-Dimer in Patients With Hematological Malignancies. *Clin. Lymphoma Myeloma Leuk.* 15, 621–626 (2015).

9. Henic, E., Borgfeldt, C., Christensen, I. J., Casslén, B. & Høyer-Hansen, G. Cleaved forms of the urokinase plasminogen activator receptor in plasma have diagnostic potential and predict postoperative survival in patients with ovarian cancer. *Clin. Cancer Res.* 14, 5785–93 (2008).

10. Sorio, C. *et al.* Elevated urinary levels of urokinase-type plasminogen activator receptor (uPAR) in pancreatic ductal adenocarcinoma identify a clinically high-risk group. *BMC Cancer* 11, 448 (2011).

11. Miyake, H. *et al.* Elevation of serum levels of urokinase-type plasminogen activator and its receptor is associated with disease progression and prognosis in patients with prostate cancer. *Prostate* 39, 123–9 (1999).

12. Fidan, E. *et al.* Diagnostic and prognostic significance of CA IX and suPAR in gastric cancer. *Med. Oncol.* 30, 540 (2013).
13. Langkilde, A. *et al.* Increased plasma soluble uPAR level is a risk marker of respiratory cancer in initially cancer-free individuals. *Cancer Epidemiol. biomarkers Prev.* 20, 609–18 (2011).
14. Garcia-Monco, J. C., Coleman, J. L. & Benach, J. L. Soluble urokinase receptor (uPAR, CD 87) is present in serum and cerebrospinal fluid in patients with neurologic diseases. *J. Neuroimmunol.* 129, 216–223 (2002).
15. Rasmussen LJH, et al. Inflammatory biomarkers and cancer: CRP and suPAR as markers of incident cancer in patients with serious nonspecific symptoms and signs of cancer. Int J Cancer. 2017 Jul 1;141(1):191-199.
16. Loosen SH et al, Serum levels of soluble urokinase plasminogen activator receptor (suPAR) predict outcome after resection of colorectal liver metastases. Oncotarget. 2018 Jun 5;9(43):27027-27038.

suPAR in endocrinology

The suPAR level is elevated in individuals that later develop type 2 diabetes, suPAR is elevated in type 1 diabetes and strongly associated with the development of diabetes complications

- Incidence of type 2 diabetes[1,2]
- Incidence and duration of type 1 diabetes[3]
- Type 1 diabetes complications[3-4]

In a Danish cohort of healthy individuals, significantly higher suPAR values were found in those who developed **type 2 diabetes**. In middle-aged non-smokers, the risk of developing diabetes was significantly higher in individuals with a high suPAR level compared to those with a low suPAR level. The increased risk remained following adjustment for fasting blood glucose, age, sex, and insulin levels. A similar risk was found in the elderly[1].

Similarly, among **overweight** individuals (BMI 25-30) with impaired glucose tolerance and a high suPAR level, an increased risk of developing diabetes is observed[2].

In **people with type 1 diabetes**, suPAR is strongly associated with the development of **diabetes complications**. In a study published in Diabetes Care (2019), 36 out of 37 patients that developed end-stage renal disease within the 6-year follow-up period were in the highest suPAR quartile. Patients in the two lowest suPAR seemed to be protected against developing renal complications[3]. Low suPAR was also protective against a decline in eGFR $\geq$30%, cardiovascular disease and mortality[3,4].

1. Haugaard SB, Andersen O, Hansen TW et al. The immune marker soluble urokinase plasminogen activator receptor is associated with new-onset diabetes in non-smoking women and men. Diabet Med. 2012 Apr;29(4):479-487

2. Heraclides A, Jensen TM, SS Rasmussen et al. The proinflammatory biomarker soluble urokinase plasminogen activator receptor (suPAR) is associated with incident type 2 diabetes among overweight but not obese individuals with impaired glucose regulation: effect modification by smoking and body weight status. Diabetologia. 2013 Apr 24

3. Theilade S, Lyngbaek S, Hansen TW, et al. Soluble urokinase plasminogen activator receptor levels are elevated and associated with complications in patients with type 1 diabetes. *J* Intern Med 2015;277

4. Rotbain Curovic V et al, Soluble Urokinase Plasminogen Activator Receptor Predicts Cardiovascular Events, Kidney Function Decline, and Mortality in Patients With Type 1 Diabetes. Diabetes Care. 2019. pii: dc181427.

suPAR in neurology

The suPAR level is associated with:

- Depression[1]
- Schizophrenia[2]
- Traumatic brain injury[3]
- Adverse childhood experiences[4]

In recent years, it has become evident that there is a biological link between chronic inflammation and psychological disorders. As suPAR is a stable marker of chronic inflammation, there have been many papers investigating suPAR as a marker of psychological disorders.

In a Danish study including 9305 blood donors with 5-years follow-up, there was a significant association between suPAR and getting medication against **depression**. For men, the risk of first use of antidepressants increased by 72% from the 1st to the 4th quartile (HR = 1.72, 95% CI: 1.11-2.69). For women, it increased by 108% from the 1st to the 4th quartile (HR = 2.08, 95% CI: 1.45-2.98)[1].

Elevated suPAR was also observed in a Swedish study of **depressed patients** (n = 19) and **suicide attempters** (n = 54), compared to healthy controls (n = 19). Both the depressed patients and suicide attempters had increased plasma suPAR. The levels of suPAR discriminated better between controls and suicide attempters than did CRP[2].

A prospective observational study aimed to explore the relationship between the plasma concentration and suPAR and **traumatic brain injury** (TBI) [3]. The suPAR levels were strongly associated with the severity of TBI patients. The suPAR levels increased in association with the severity

of brain injury, the significance being found among all three groups: severe, moderate and mild TBI. The suPAR levels in non-survivals were significantly increased compared to the survivals (P < 0.05). Thus, the authors conclude that prognosis was worse in the patients with elevated suPAR[3]

Finally, a study of childhood risk factors and the suPAR level at age 38 carried out in the Dunedin study[4]. After controlling for sex, body mass index (BMI), and smoking, children who experienced more **adverse childhood experiences**, lower IQ, or had poorer self-control showed elevated adult suPAR. The authors conclude that exposure to more childhood risk factors was associated with higher suPAR levels, independent of CRP, and that suPAR is a useful addition to studies connecting childhood risk to adult inflammatory burden[4].

1. Haastrup E et al. Soluble urokinase plasminogen activator receptor as a marker for use of antidepressants. PLoS One. 2014 ;9(10):e110555.
2. Ventorp F et al. Increased Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) Levels in Plasma of Suicide Attempters. PLoS One. 2015 9;10(10):e0140052.
3. Yu L Et al. Diagnostic and prognostic significance 0f suPAR in traumatic brain injury. Neurol India. 2014 Sep-Oct;62(5):498-502
4. Rasmussen LJHH et al, Cumulative childhood risk is associated with a new measure of chronic inflammation in adulthood. J Child Psychol Psychiatry. 2019 60(2):199-208

suPAR in cardiovascular diseases

The suPAR level is elevated in patients with cardiovascular diseases compared to healthy individuals, and elevated suPAR level is associated with:

- Atherosclerosis[1]
- Ischemic heart disease[2,13,21]
- Poor prognosis[2,16,18,19]
- Venous thromboembolism[20]

As well as the incidence of:

- Cardiovascular diseases in the general population[7-11]

suPAR is a promising biomarker of cardiovascular diseases, as it reflects low-grade inflammation (chronic inflammation) and is associated with lifestyle factors like smoking, alcohol, and an inactive lifestyle. Previous studies have shown that the **uPA/uPAR-system** plays a key role in the **pathogenesis of atherosclerosis**[1]. Physiologically the system is involved in **fibrinolysis**, **angiogenesis**, and **immune function**, including leucocyte migration, proliferation, and matrix degradation during tissue remodelling in the atherosclerotic plaque[2]. uPAR is expressed in various cells involved in the development of atherosclerosis, including macrophages, endothelial cells, and smooth muscle cells, and an accumulation of uPAR in the atheroma has been found[3]. uPAR plays a role in **the coagulation cascade** during plasminogen activation and fibrinolysis[4]. So far, no causal relationship between the urokinase system and atherosclerosis or cardiovascular diseases has been shown[2]. However, new data have demonstrated an association between suPAR and focal segmental glomerulosclerosis. The kidneys play a key role in blood pressure and fluid balance regulation, and therefore suPAR may be associated with heart failure and myocardial strain[5,6]. A similar suPAR-

mediated effect on endothelial cells and platelets may potentially play a role in vascular inflammation and thrombosis[5].

In five large studies, including a total of 4866 individuals[7-11], suPAR is a predictor of **cardiovascular morbidity and mortality in the general population** even after adjustment for the well-validated Framingham risk score[11] and taking into account well-known risk factors, CRP, and other biomarkers associated with cardiovascular diseases. In general, the prognostic value of baseline suPAR level appears to be strongest in the younger age groups and males[11].

In patients with **ST-segment elevation myocardial infarction (STEMI)** treated with primary PCI, the suPAR level is elevated the first 24 hours after admission. Following adjustment for traditional risk factors, age, sex, CRP, creatinine, troponin T, total cholesterol, diabetes, and hypertension, suPAR remains associated with mortality and a **new myocardial infarction[2]**. In non-survivors, baseline suPAR values are significantly higher than in survivors (4.9 ng/mL vs. 3.9 ng/mL), and all-cause mortality increases significantly with higher suPAR values[2].

Following adjustment for sex and age, suPAR was associated with an increased risk of developing **atrial fibrillation**. However, this association disappeared following adjustment for well-known risk factors[6].

In **uremic patients** receiving peritoneal dialysis or hemodialysis, the suPAR level and the carotid intima-media thickness (IMT) in the two dialysis groups are significantly higher than in healthy age- and sex-matched controls. In a smaller study, suPAR is associated with IMT[12].

suPAR is also a prognostic marker of **cardiovascular diseases in patients with mild to moderate chronic renal diseases**, including cardiac mortality, non-fatal MI, myocardial ischemia, coronary intervention, ischemic stroke, and newly diagnosed peripheral vascular diseases[13]. suPAR and eGFR are comparable in estimating

mortality risk, and in this population, suPAR was a stronger cardiovascular risk predictor than eGFR[13].

In patients admitted with suspected **acute coronary syndrome (ACS)**, suPAR is a strong predictor of mortality and readmission due to heart failure and a **new myocardial infarction**. Thus, in non-survivors, the baseline suPAR level was significantly higher than in survivors, and, similarly, the suPAR level was higher in readmitted patients than in non-readmitted patients. The study concluded that in patients with suspected ACS, suPAR improves risk stratification beyond traditional risk factors[16].

In a South African study, the baseline suPAR level could not predict the development of **hypertension. However,** on the other hand, a change in suPAR level was to some extent associated with increasing blood pressure during the observation period[17].

In patients resuscitated from a **cardiac arrest** and treated with hypothermia, suPAR was studied as a potential prognostic tool. One study found that the suPAR level 6 hours after cardiac arrest was strongly associated with mortality and neurological outcome[18]. Similarly, in another study, suPAR was strongly associated with mortality but not with neurological outcome[19]. In patients with non-shockable rhythms, the baseline suPAR level was significantly higher than in patients with shockable rhythms[19].

High suPAR levels are associated with the incidence of **venous thromboembolism**[20]. No significant association between pulmonary embolism and suPAR was found[20].

In males and females with **carotid plaques**, the suPAR level is significantly higher than in individuals with no carotid plaques[21,10]. Similarly, suPAR is a predictor of **ischemic heart disease (IHD)**, and in patients with both elevated suPAR level and carotid plaques, the risk of developing IHD is significantly increased[21].

Following adjustment for traditional risk factors and subclinical organ damage, suPAR remains associated with **cardiovascular mortality**[10].

Furthermore, in a study of 1126 Danes, it was shown that suPAR can predict **coronary artery calcifications** in healthy individuals, as assessed by cardiac CT scan, and that suPAR is associated with calcium score[8].

Surgical stress related to **coronary bypass** does not induce significant changes in suPAR level 6 or 24 hours postoperatively compared to the preoperative value[23].

Finally, suPAR levels were determined in 1314 patients presenting to the emergency department with suspected AMI. Patients were followed up for 12 months to assess all-cause mortality. suPAR levels reliably predicted all-cause mortality after 1 year. The hazard ratio for 1-year mortality was 12.6 ($p < 0.001$) in the highest suPAR quartile compared to the lowest suPAR quartile[24]. The prognostic value for 6-month mortality was comparable to an established risk prediction model, the Global Registry of Acute Coronary Events (GRACE) score, with an AUC of 0.79 (95% CI 0.72-0.86) for the GRACE score and 0.77 (95% CI 0.69-0.84) for suPAR. The addition of suPAR improved the GRACE score, as shown by integrated discrimination improvement statistics of 0.036 ($p = 0.03$), suggesting **further discrimination of events from non-events by the addition of suPAR**[24]

1. Fuhrman B. The urokinase system in the pathogenesis of atherosclerosis. *Atherosclerosis.* 2012;222(1):8-14.
2. Lyngbaek S, Marott JL, Moller DV, et al. Usefulness of soluble urokinase plasminogen activator receptor to predict repeat myocardial infarction and mortality in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous intervention. *Am J Cardiol.* 2012;110(12):1756-1763.
3. Edsfeldt A, Nitulescu M, Grufman H, et al. Soluble urokinase plasminogen activator receptor is associated with inflammation in the vulnerable human atherosclerotic plaque. *Stroke.* 2012;43(12):3305-3312.
4. Blasi F, Sidenius N. The urokinase receptor: focused cell surface proteolysis, cell adhesion and signaling. *FEBS Lett.* 2010;584(9):1923-1930.

5. Hayek SS, Sever S, Ko YA, et al. Soluble Urokinase Receptor and Chronic Kidney Disease. *N Engl J Med.* 2015;373(20):1916-1925.
6. Borne Y, Persson M, Melander O, Smith JG, Engstrom G. Increased plasma level of soluble urokinase plasminogen activator receptor is associated with incidence of heart failure but not atrial fibrillation. *Eur J Heart Fail.* 2014;16(4):377-383.
7. Botha S, Fourie CM, Schutte R, Eugen-Olsen J, Pretorius R, Schutte AE. Soluble urokinase plasminogen activator receptor as a prognostic marker of all-cause and cardiovascular mortality in a black population. *Int J Cardiol.* 2015;184:631-636.
8. Sorensen MH, Gerke O, Eugen-Olsen J, et al. Soluble urokinase plasminogen activator receptor is in contrast to high-sensitive C-reactive-protein associated with coronary artery calcifications in healthy middle-aged subjects. *Atherosclerosis.* 2014;237(1):60-66.
9. Eugen-Olsen J, Andersen O, Linneberg A, et al. Circulating soluble urokinase plasminogen activator receptor predicts cancer, cardiovascular disease, diabetes and mortality in the general population. *J Intern Med.* 2010;268(3):296-308.
10. Sehestedt T, Lyngbaek S, Eugen-Olsen J, et al. Soluble urokinase plasminogen activator receptor is associated with subclinical organ damage and cardiovascular events. *Atherosclerosis.* 2011;216(1):237-243.
11. Lyngbaek S, Marott JL, Sehestedt T, et al. Cardiovascular risk prediction in the general population with use of suPAR, CRP, and Framingham Risk Score. *Int J Cardiol.* 2013;167(6):2904-2911.
12. Pawlak K, Mysliwiec M, Pawlak D. The urokinase-type plasminogen activator/its soluble receptor system is independently related to carotid atherosclerosis and associated with CC-chemokines in uraemic patients. *Thromb Res.* 2008;122(3):328-335.
13. Meijers B, Poesen R, Claes K, et al. Soluble urokinase receptor is a biomarker of cardiovascular disease in chronic kidney disease. *Kidney Int.* 2015;87(1):210-216.
14. Pawlak K, Pawlak D, Mysliwiec M. Tissue factor and urokinase-type plasminogen activator system are related to the presence of cardiovascular disease in hemodialysis patients. *Thromb Res.* 2007;120(6):871-876.
15. Intzilakis T, Hartmann G, Mouridsen MR, et al. Soluble urokinase plasminogen activator receptor, C-reactive protein and triglyceride are associated with heart rate variability in non-diabetic Danes. *Eur J Clin Invest.* 2013;43(5):457-468.
16. Lyngbaek S, Andersson C, Marott JL, et al. Soluble urokinase plasminogen activator receptor for risk prediction in patients admitted with acute chest pain. *Clin Chem.* 2013;59(11):1621-1629.
17. Botha S, Fourie CM, Schutte R, Eugen-Olsen J, Schutte AE. Soluble urokinase plasminogen activator receptor and hypertension among black South Africans after 5 years. *Hypertens Res.* 2015;38(6):439-444.
18. Rundgren M, Lyngbaek S, Fisker H, Friberg H. The inflammatory marker suPAR after cardiac arrest. *Ther Hypothermia Temp Manag.* 2015;5(2):89-94.
19. Jalkanen V, Vaahersalo J, Pettila V, et al. The predictive value of soluble urokinase plasminogen activator receptor (SuPAR) regarding 90-day mortality and 12-month neurological outcome in critically ill patients after out-of-hospital cardiac arrest. Data from the prospective FINNRESUSCI study. *Resuscitation.* 2014;85(11):1562-1567.
20. Engstrom G, Zoller B, Svensson PJ, Melander O, Persson M. Soluble urokinase plasminogen activator receptor and incidence of venous thromboembolism. *Thromb Haemost.* 2015;115(3).
21. Persson M, Ostling G, Smith G, et al. Soluble urokinase plasminogen activator receptor: a risk factor for carotid plaque, stroke, and coronary artery disease. *Stroke.* 2014;45(1):18-23.
22. Mekonnen G, Corban MT, Hung OY, et al. Plasma soluble urokinase-type plasminogen activator receptor level is independently associated with coronary microvascular function in patients with non-obstructive coronary artery disease. *Atherosclerosis.* 2015;239(1):55-60.
23. Gozdzik W, Adamik B, Gozdzik A, Rachwalik M, Kustrzycki W, Kubler A. Unchanged plasma levels of the soluble urokinase plasminogen activator receptor in elective coronary artery bypass graft surgery patients and cardiopulmonary bypass use. PLoS One. 2014;9(6):e98923.

24   Sörensen NA et al. Predictive value of soluble urokinase-type plasminogen activator receptor for mortality in patients with suspected myocardial infarction. Clin Res Cardiol.2019 doi: 10.1007/s00392-019-01475-1.

suPAR in pulmonary diseases

The suPAR level is elevated in patients with infections and chronic diseases of the lungs and respiratory tract compared to healthy individuals, and a high suPAR level is associated with:

- Bacteremia and sepsis[1-4]
- Pneumonia[5-7]
- Asthma and poor disease control in asthma[8]
- COPD and in relation to an exacerbation[9,10]
- Incidence of future respiratory cancer[11]
- Poor prognosis[1-7]

In general, the suPAR level reflects immune activation regardless of etiology, and therefore the suPAR level is of no diagnostic value. However, in **SIRS** patients, it has been demonstrated that the suPAR level can discriminate patients with **bacteremia** from patients with no bacteremia. A combined model using suPAR, procalcitonin, and IL-6 showed an AUC of 0.804 to predict bacteremia in SIRS patients[1].

The **prognostic** value of suPAR has been studied among patients with *S. pneumoniae* **bacteremia**[2] and in patients with *S. pneumoniae*, *S. aureus* or *E. coli* bacteremia[3]. In both situations, significantly higher suPAR values were found in non-survivors. In the bacteremia patients, a sensitivity of 83% and a specificity of 76% for mortality is found using a cut-off value of 11.0 ng/mL. A similar prognostic value is found in a study of patients with sepsis. Here, a cut-off value of 12 ng/mL is linked to a >80% sensitivity and a negative predictive value of 94.5% for mortality[4]. In mechanically ventilated **patients**[5] and **children with pneumonia**[6,7], the suPAR level is elevated and associated with the seriousness of the disease and a poorer prognosis.

The suPAR level correlates with respiratory obstruction and can potentially help with the objective assessment of **asthma**[8]. In addition, the median suPAR level is significantly higher in asthmatics compared to healthy individuals (3.3 ng/mL vs 2.5 ng/mL)[9].

Similarly, in **COPD patients**, the suPAR level is significantly higher than in healthy individuals. The median level is above the level in asthma patients (5.8 ng/mL vs 3.3 ng/mL)[9].

Serum suPAR, CRP, and fibrinogen are significantly higher in **COPD patients experiencing an exacerbation** compared to healthy controls (4.8 ± 1.9 ng/mL vs 2.4 ± 0.9 ng/mL, respectively). suPAR was superior to fibrinogen and CRP in identifying COPD patients experiencing an exacerbation. In multivariable analyses, only suPAR and fibrinogen were predictors of an exacerbation. Moreover, a negative correlation between suPAR and lung function, measured by **FEV1**, was found[10].

In the general population, suPAR is associated with the incidence of **respiratory cancer**, even after adjustment for traditional risk factors, CRP, and leucocytes[11].

In a study including 2838 acutely admitted medical patients with COPD as primary (AECOPD) or secondary diagnose, median suPAR levels were significantly higher among patients who died within 30 days compared with those who survived (5.7 ng/ml (IQR 3.8-8.1) vs 3.6 ng/ml (2.7-5.1), $P < 0.0001$)[12]

1. Hoenigl, M., Raggam, R.B., Wagner, J., Valentin, T., Leitner, E., Seeber, K., Zollner- Schwetz, I., Krammer, W., Prüller, F., Grisold, A.J., Krause, R., 2013. Diagnostic accuracy of soluble urokinase plasminogen activator receptor (suPAR) for prediction of bacteremia in patients with systemic inflammatory response syn- drome. Clin. Biochem. 46, 225–229.
2. Wittenhagen, P., Kronborg, G., Weis, N., Nielsen, H., Obel, N., Pedersen, S.S., Eugen-Olsen, J., 2004. The plasma level of soluble urokinase receptor is elevated in patients with Streptococcus pneumoniae bacteraemia and predicts mortality. Clin. Microbiol. Infect. 10, 409–415.
3. Huttunen, R., Syrjanen, J., Vuento, R., Hurme, M., Huhtala, H., Laine, J., Pessi, T., Ait- toniemi, J., 2011. Plasma level of soluble urokinase-type plasminogen activator receptor as a predictor of disease severity and case fatality in patients with bacteraemia: a prospective cohort study. J. Intern. Med. 270, 32–40.

4. Giamarellos-Bourboulis EJ, Norrby-Teglund A, Mylona V, Savva A, Tsangaris I,Dimopoulou I, et al. Risk assessment in sepsis: a new prognostication rule by APACHE II score and serum soluble urokinase plasminogen activator receptor. Crit Care 2012;16:R149.
5. Savva, A., Raftogiannis, M., Baziaka, F., Routsi, C., Antonopoulou, A., Koutoukas, P., Tsaganos, T., Kotanidou, A., Apostolidou, E., Giamarellos-Bourboulis, E.J., Dimopoulos, G., 2011. Soluble urokinase plasminogen activator receptor (suPAR) for assessment of disease severity in ventilator-associated pneumonia and sepsis. J. Infect. 63, 344–350.
6. Wrotek, A., Pawlik, K., Jackowska, T., 2013. Soluble receptor for urokinase plasmino- gen activator in community-acquired pneumonia in children. Adv. Exp. Med. Biol. 788, 329–334.
7. Wrotek, A., Jackowska, T., Pawlik, K., 2015. Soluble urokinase plasminogen activator receptor: an indicator of pneumonia severity in children. Adv. Exp. Med. Biol. 835, 1–7, http://dx.doi.org/10.1007/5584 2014 40
8. Ivancsó, I., Toldi, G., Bohács, A., Eszes, N., Müller, V., Rigó Jr., J., Vásárhelyi, B., Losonczy,G., Tamási, L., 2013. Relationship of circulating soluble urokinase plasminogenactivator receptor (suPAR) levels to disease control in asthma and asthmaticpregnancy. PLoS ONE 8, e60697.
9. Portelli M, Siedlinski M, Stewart C et al. Genome-wide protein QTL mapping identifies human plasma kallikrein as a post-translational regulator of serum uPAR levels. FASEB J. 2014 Feb;28(2):923-34
10. Gumus A, Altintas N, Cinarka H, Kirbas A, Hazıroglu M, Karatas M¹, Sahin U. Soluble urokinase-type plasminogen activator receptor is a novel biomarker predicting acute exacerbation in COPD.Int J Chron Obstruct Pulmon Dis. 2015 Feb 13;10:357-65.
11. Langkilde A, Hansen TW, Ladelund S, Linneberg A, Andersen O, Haugaard SB, Jeppesen J, Eugen-Olsen J Increased plasma soluble uPAR level is a risk marker of respiratory cancer in initially cancer-free individuals.Cancer Epidemiol Biomarkers Prev. 2011 Apr;20(4):609-18.
12. Godtfredsen NS, Jørgensen DV,, Marsaa K, Ulrik CS,, Andersen O, Eugen-Olsen J, Rasmussen LJH. Soluble urokinase plasminogen activator receptor predicts mortality in exacerbated COPD. Respir Res. 2018 21;19(1):97.

suPAR in gastroenterology

The following factors are associated with an **elevated** suPAR level:

- Cirrhosis[1,2,5]
- Alcoholic liver disease[3]
- Excessive alcohol consumption[3]
- non-alcoholic fatty liver disease. [4]
- Acute liver failure[6, 8]
- Alcoholic pancreatitis[7]
- Poor prognosis[1-5,7]

In addition, an elevated suPAR level is associated with **future** incidence of:

- Hepatocellular carcinoma[8]

Inflammation plays a key role in the development of chronic hepatic diseases. As suPAR is a marker of inflammation, the diagnostic and prognostic value of suPAR in hepatic diseases has been studied.

The suPAR level is significantly higher in **patients with cirrhosis** compared to healthy controls[1,2]. In a study of 159 patients with **chronic hepatic diseases**, including 98 patients with cirrhosis, the diagnostic ability of suPAR in identifying cirrhosis was good, and suPAR was a strong predictor of mortality or need of transplantation. A cut-off level >9 ng/mL predicted a poor prognosis with a sensitivity and specificity of 70.7% and 77.8%, respectively, as well as a relative risk of 8.5 (3.5-20.3)[1].

The suPAR level is higher in patients with alcoholic etiology and correlates positively with fibrosis[1,3,4]. In addition, the suPAR level is higher in individuals with **excessive alcohol consumption** compared to healthy individuals[3].

In patients with **decompensated cirrhosis**, the suPAR level is significantly higher (median 12.9 ng/mL) than in patients with compensated cirrhosis (8.9 ng/mL), and suPAR is associated with 28-day mortality[5].

In patients with **spontaneous bacterial peritonitis**, an elevated suPAR level in ascites fluid was found, and the level was associated with severity and prognosis[5].

A small study of patients with acute liver failure showed a high median suPAR level of 13.2 ng/mL. Similarly, a strong correlation between suPAR and declining liver function (increasing AST/ALT and INR), independently of the etiology, was found[6].

A study of 104 patients shows that the suPAR level on admission was superior to CRP, hematocrit, and creatinine as a prognostic marker of the severity of **acute alcoholic pancreatitis**. Using a cut-off value of 5 ng/mL, the sensitivity and specificity for predicting moderate or severe pancreatitis were 79% and 78%, respectively. The suPAR level was significantly associated with severity: Mild and moderate/serious: 4.2 ng/mL vs 6.2 ng/mL, respectively[7].

1. Zimmerman HW, Koch A, Seidler S et al. Circulating soluble urokinase plasminogen activator is elevated in patients with chronic liver disease, discriminates stage and etiology of cirrhosis ans predicts prognosis. Liver Int. 2012 Mar;32(3):500-509.
2. Wiese S, Mortensen C, Gøtze JO. Cardiac and proinflammatory markes predict prognosis in cirrhosis. Liver Int. 2014 Jul;34(6):e19-30.
3. Tuomi, Heidi, et al. "Serum soluble urokinase plasminogen activator receptor in alcoholics: Relation to liver disease severity, fibrogenesis, and alcohol use." J Gastroenterolo Hepatic 2014 Dec;29(12): 1991-1995.
4. Sjöwall C, Martinsson K, Cardell K et al. Soluble urokinase plasminogen activator receptor levels are associated with severity of fibrosis in non-alcoholic fatty liver disease. Trails Res. 2015 Jun;165(6):658.666.
5. Zimmermann HW, Reuken PA, Koch A, et al. Soluble urokinase plasminogen activator receptor is compartmentally regulated in decompensated cirrhosis and indicates immune activation and short-term mortality. J Intern Med 2013; 274: 86–100 Koch A, Zimmerman H, Gassler N et al. Clinical relevance and cellular source of elevated soluble urokinase plasminogen activator receptor in acute liver failure. Liver int. 2014 Oct;34(9):1330-1339.
6. Nikkola, A., Aittoniemi, J. J., Huttunen, R., Sand, J., & Laukkarinen,J. (2015). Mo1351 Systemic Levels of Soluble Urokinase-Type Plasminogen Activator Receptor (suPAR) Predict the Severity of Acute Alcohol Pancreatitis. *Gastroenterology*, *148*(4), S-680.
7. Chounta, A. *et al*. Serum soluble urokinase plasminogen activator receptor as a screening test for the early diagnosis of hepatocellular carcinoma. *Liver Int.* 35, 601–607 (2015)

8. Loosen SH et al, Serum levels of soluble urokinase plasminogen activator receptor (suPAR) predict outcome after resection of colorectal liver metastases. Oncotarget. 2018 5;9(43):27027-27038.

suPAR in nephrology

The suPAR level is associated with:

- Chronic renal diseases[3]
- Future incidence of chronic renal diseases[4]
- Declining eGFR[4,5]

In the kidneys, suPAR plays a role in regulating the permeability of the glomerular filtration barrier, and suPAR may be involved in podocyte damage and development of **focal segmental glomerulosclerosis** and **diabetic nephropathy**[1,2].

The suPAR level increases in **patients with chronic renal diseases** and a high level is significantly associated with mortality and incidence of cardiovascular diseases in these patients[3].

The association between suPAR and chronic renal diseases has been further studied in a large study[4]. It was found that the suPAR level was an independent predictor of **declining eGFR**. During the study follow-up period of 3.7 years, the decline in eGFR in subjects in the lower suPAR quartile was 0.9 mL/min/1.73 m^2 and 4.2 mL/min/1.73 m^2 in the upper quartile.

In 1335 individuals with an eGFR >60 mL/min/1.73 m^2 at study start, a suPAR level in the upper quartile was associated with a significantly increased **incidence of chronic renal diseases** compared to those in the lower quartile; all in all, a 3-fold increased risk[4].

In patients with **primary and secondary glomerulonephritis**, an elevated suPAR level is similarly associated with reduced eGFR and the presence of **proteinuria**[5].

Reduced renal function causes a significant increase in suPAR level, and in hemodialysis patients, the mean value is 14.8 ng/mL. In this group of patients, a high level is associated with increased mortality and increased risk of hospitalization[6].

Another recent study supporting the strong link between suPAR and development of kidney disease comes from a study of patients with type 1 diabetes who were elevated suPAR associated with increased risk of fast eGFR decline and end-stage renal disease[7].

Finally, suPAR both associates and causes acute kidney injury, according to a publication in NEJM 2020[8].

1. Wei c, El Hindi S, Li J et al. Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat Med 2011;17:952-60.
2. Yoo H, Pedigo CE, Guzman J. Sphingomyelinase-like phosphodiesterase 3b expression levels determine podocyte injury phenotypes in glomerular disease. J AM Soc Nephrol 2015 jan;26(1):133-47
3. Meijers B, Poesen R, Claes K et al. Soluble urokinase receptor is a biomarker of cardiovascular disease in chronic kidney disease. Kidney Int 2015 Jan;87(1):210-216.
4. Hayek S, Sever S, Ko Y et al. Soluble urokinase receptor and chronic kidney disease. N Engl J Med. 2015 Nov 12; 373(20):1916-25.
5. Musetti C, Quaglia M, Cena T et al. Circulating suPAR levels are affected by glomerular filtration rate and proteinuria in primary and secondary glomerulonephritis. J Nephrol 2015 Jun;28(3):299-305.
6. Griveas I, Andpriopoulos C, Sitaras P et al. Soluble urokinase plasminogen receptor: A future risk marker for hemodialysis patients Nephrol. Dial. Transplant 2015;30(suppl 3)
7. Rotbain Curovic V et al, Soluble Urokinase Plasminogen Activator Receptor Predicts Cardiovascular Events, Kidney Function Decline, and Mortality in Patients With Type 1 Diabetes. Diabetes Care. 2019. pii: dc181427.
8. Hayek SS et al, Soluble Urokinase Receptor and Acute Kidney Injury. N Engl J Med. 2020 Jan 30;382(5):416-426. doi: 10.1056/NEJMoa1911481

suPAR in intensive care

In critically ill patients, the suPAR level is significantly increased. suPAR is an independent prognostic marker, and the change over time correlates with organ dysfunction.

suPAR is elevated and has a prognostic value in patients with:

- SIRS (systemic inflammatory response syndrome)[1,2]
- Sepsis/septic shock[3-9]
- Burn injuries[10]
- Traumatic brain injuries[11]

The suPAR level reflects the body's immune response to infections, and the level increases with the **severity of the infection**. In patients with **organ dysfunction**, the suPAR value is often a two-digit value. In particular, hepatic and renal dysfunction affects the suPAR level[3-5].

suPAR has been studied in **patients with SIRS** who were acutely admitted to the emergency department (n=902). The studies showed that suPAR is a stronger marker of 2-day, 30-day, and 90-day mortality than age, CRP, IL-6, creatinine, and procalcitonin. However, for diagnostic purposes, IL-6 and CRP are superior to suPAR in predicting a positive blood culture[1,2].

A Greek multicenter study including 1914 **patients with sepsis** showed that suPAR is a strong predictor of mortality. A suPAR level above 12 ng/mL is linked to a >80% sensitivity for mortality and a negative predictive value of 94.5%[6].

In addition, the prognostic value of suPAR in patients with sepsis is independent of relevant covariates like APACHE score, CRP, etc.[6-9].

In patients with **burn injuries** and **inhalation trauma** requiring mechanical ventilation, the plasma suPAR level and BAL fluid level

correlate to IL-6 and coagulation factors. An elevated plasma suPAR level is associated with prolonged ICU stay and the duration of mechanical ventilation[10].

The suPAR level is elevated in patients with **traumatic brain injury**. In trauma patients who suffered a brain injury within 12 hours before blood sampling, the mean suPAR level is 14.9 ng/mL ± 6.9 vs 2.8 ng/mL ± 0.7 in control subjects. In these patients, suPAR is associated with the severity of the brain injury and with mortality[11].

1. Raggam RB, Wagner J, Pruller F et al. Soluble urokinase plasminogen activator receptor predicts mortality in patients with systemic inflammatory response syndrome. J Intern Med 2014;276(6):651-658.
2. Koch A, Tacke F. Why high suPAR is not super--diagnostic, prognostic and potential pathogenic properties of a novel biomarker in the ICU. Crit Care 2011;15(6):1020.
3. Koch A, Voigt S, Kruschinski C et al. Circulating soluble urokinase plasminogen activator receptor is stably elevated during the first week of treatment in the intensive care unit and predicts mortality in critically ill patients. Crit Care 2011;15(1):R63.
4. Koch A, Zimmermann HW, Gassler N et al. Clinical relevance and cellular source of elevated soluble urokinase plasminogen activator receptor (suPAR) in acute liver failure. Liver Int 2014;34(9):1330-1339.
5. Meijers B, Poesen R, Claes K et al. Soluble urokinase receptor is a biomarker of cardiovascular disease in chronic kidney disease. Kidney Int 2015;87(1):210-216.
6. Giamarellos-Bourboulis EJ, Norrby-Teglund A, Mylona V et al. Risk assessment in sepsis: a new prognostication rule by APACHE II score and serum soluble urokinase plasminogen activator receptor. Crit Care 2012;16(4):R149.
7. Donadello K, Scolletta S, Covajes C, Vincent JL. suPAR as a prognostic biomarker in sepsis. BMC Med 2012;10:2. doi: 10.1186/1741-7015-10-2.:2-10.
8. Backes Y, van der Sluijs KF, Mackie DP et al. Usefulness of suPAR as a biological marker in patients with systemic inflammation or infection: a systematic review. Intensive Care Med 2012;38(9):1418-1428.
9. Eugen-Olsen J, Giamarellos-Bourboulis EJ. suPAR: The unspecific marker for disease presence, severity and prognosis. Int J Antimicrob Agents 2015;(15):10.
10. Backes Y, van der Sluijs KF, Tuip de Boer AM et al. Soluble urokinase-type plasminogen activator receptor levels in patients with burn injuries and inhalation trauma requiring mechanical ventilation: an observational cohort study. Crit Care 2011;15(6):R270.
11. Yu L, Wu X, Wang H, et al.. Diagnostic and prognostic significance of suPAR in traumatic brain injury. Neurol India 2014;62(5):498-502.

suPAR in surgery

A high preoperative suPAR level is associated with:

- Post operative complications
- Increased mortality risk[3]
- Poor prognosis[5,6,8-10]
- Postoperative pneumonia[7]
- Prosthetic joint infection[11]

suPAR is a well-studied biomarker predicting prognosis, disease severity, and organ dysfunction and is considered a marker of the individual's inflammatory status. It has been demonstrated that biomarkers can improve triage and identify high and low-risk patients among acutely admitted patients[1]. Improving the preoperative risk stratification using biomarkers may optimise the patient's clinical outcome[2]. Available data on the use of biomarkers and risk stratification have to date been observational data, and suPAR has mainly been studied in medical and oncological patients.

Gastric surgery patients and orthopedic surgery patients were included in a study conducted in the emergency department at Hillerød Hospital, Denmark. The TRIAGE study included 5992 unselected patients and confirmed the prognostic value of suPAR regarding mortality, and found it similar in both medical and surgical patients.
The same study showed that triage based on suPAR level was superior to the current triage system in predicting 30-day mortality: AUC 0.84 (0.82-0.87) vs. 0.62 (0.58-0.66), respectively. In multivariate analyses of 30-day mortality in relation to suPAR quartiles, adjusted for sex, age, CRP, leucocytes, and triage category, HR was 1.0, 2.2, 8.3, and 26.9 in the upper quartile[3]. Of the acute medical patients, 697 had a surgical intervention registered within 3 months after admission. During a 90-day follow-up from surgery, 31 (7.0%) patients

died, and 158 (35.6%) patients had postoperative complications. After adjusting for age, sex, and ASA classification, the HR for 90-day postoperative mortality was 2.5 (95% CI 1.6-4.0) for every doubling of suPAR level. suPAR was significantly better than CRP at predicting mortality and all complications (P = 0.0036 and P = 0.0041, respectively). Combining ASA classification and suPAR level significantly improved prediction of mortality and the occurrence of a postoperative complication within 90 days after surgery (P < 0.0001)[12].

In acute medical patients, elevated suPAR is associated with an increased risk of acute surgery

Acutely admitted medical patients are often fragile and at risk of future surgery. A Danish group investigated if suPAR also predicts acute surgery, which is associated with higher mortality than elective surgery, and predicts postoperative mortality[13]. In a retrospective registry-based cohort study of 17,312 patients, acute surgery was carried out on 2404 patients (13.9%) after a median of 45 days (IQR 5-186) following the index admission. Patients receiving acute surgery had higher baseline suPAR compared with patients receiving elective- or no surgery (p < 0.0001). The hazard ratio (HR) for acute surgery was 1.50 (95% confidence interval (CI): 1.42-1.59) for every doubling of the suPAR level in the adjusted Cox regression analysis. Death within 90 days occurred in 439 (18.3%) patients receiving acute surgery, and the adjusted HR for postoperative mortality was 1.73 (95% CI: 1.52-1.95). The authors conclude that elevated levels of suPAR in acutely admitted medical patients were **independently associated with increased risk of future acute surgery** as well as with 90-day postoperative mortality[13].

A high suPAR level has been demonstrated in both tumor tissue and blood, and in several cancers, the suPAR level is shown to correlate with a poor prognosis[4]. In a few studies, suPAR has been studied as a potential biomarker in gastric surgery.

In a cohort of 518 elective **colorectal cancer patients**, preoperative measurement of the suPAR level was performed. In multivariate analyses adjusted for age, sex, tumor classification, and localisation, suPAR was significantly associated with mortality, HR 1.74 (1.33-2.26; p<0.0001). In addition, the suPAR level was associated with tumor stage and localisation; and in **colon cancer** patients, the suPAR level was significantly higher compared to **rectal cancer** patients[5]. The same cohort was also followed in another study, in which the suPAR plasma level was found to be an independent prognostic marker[6].

To identify risk patients among elective **colon cancer patients,** the suPAR level was studied. In patients receiving **blood transfusion** during surgery, the suPAR level was higher, and a significant association between the suPAR level and **postoperative infections** was shown. Occurrence of **pneumonia** was significantly associated with the suPAR level, but any significant association with other infectious complications could not be found[7].

In patients with **gastric cancer**, the suPAR level was significantly higher compared to healthy controls (2.3 ng/mL ± 0.77), and the suPAR level was significantly higher in cancer patients with metastatic disease (7.0 ng/mL ± 6.1) than in patients with no metastases (4.8 ng/mL ± 4.4). In the group of patients with a suPAR value above 5.2 ng/mL, the mortality was significantly increased[8].
In patients with rectal cancer[9] and colon cancer[10], a similar prognostic value is found, indicating an increased mortality risk.

suPAR in orthopedic surgery
The diagnostic value of suPAR in **prosthetic knee/hip joint infection** has been examined in a study. The study included 80 patients, of which 45 experienced prosthetic joint infection defined by the presence of clinical signs (swelling, redness, tenderness, and pus inside the joint) and a positive culture. A significantly higher median

suPAR level (6.8 ng/mL) was found in these patients compared to patients without infection who had revision surgery done. Furthermore, suPAR was positively correlated with CRP, and the study showed that suPAR was more precise in diagnosing prosthetic knee/hip joint infection than CRP[11].

1. Schuetz P, Hausfater P, Amin A et al. Biomarkers from distinct biological pathways improve early risk stratification in medical emergency patients: the multinational, prospective, observational TRIAGE study. Critical Care (2015) 19:377
2. Biccard BM, Devereaux PJ, Rodseth RN. Cardiac biomarkers in the prediction of risk in the non-cardiac surgery setting. Anaesthesia 2014; 69: 484-493.
3. Østervig RM, Køber L, Forberg JL, Rasmussen LS, Eugen-Olsen J, Iversen K. suPAR—a future prognostic biomarker in emergency medicine. Scand J Trauma Resusc Emerg Med 2015;23(Suppl 1):A31.
4. Kjellman A, Akre O, Gustafsson O et al. Soluble urokinase plasminogen acitvator receptor as a prognostic marker in men participating in prostate cancer screening. J. intern Med. 2011 Mar;269(3):299-305.
5. Lomholt AF, Christensen IJ, Høyer-Hansen G et al. Prognostic value of intact and cleaved forms of the urokinase plasminogen activator receptor in a retrospective study of 518 colorectal cancer patients. Acta Oncology 2010; 49:805-811
6. Stephens RW1, Nielsen HJ, Christensen IJ, Thorlacius-Ussing O, Sørensen S, Danø K, Brünner N. Plasma urokinase receptor levels in patients with colorectal cancer: relationship to prognosis.J Natl Cancer Inst. 1999 May 19;91(10):869-74.
7. Svendsen MN, Ytting H, Brünner N et al. Preoperative concentrations of suPAR and MBL proteins are associated with the development of pneumonia after elective surgery for colorectal cancer. Surg Infect (Larchmt) 2006 okt;7(5): 463-471.
8. Fidan E, Mentese A, Ozedemir F. Diagnostic and prognostic significance of CA IX and suPAR in gastric cancer. Med oncol 2013 jun;30(2):540
9. Fernebro E, Madsen RR, Fernö M et al. Prognostic importance of the soluble plasminogen activator receptor, suPAR, in plasma from rectal cancer pateints. Eur j cancer 2000; 486-491.
10. Stephens RW, Nielsen HJ, Christensen IJ. Plasma urokinase recptor levels in patients with colorectal cancer: relationship to prognosis. J natl Cancer Inst 1999, 91, 869-874.
11. Galliera E, Drago L, Marazzi MG. Soluble urokinase-type plasminogen activator receptor (suPAR) as new biomarker of the prosthetic joint infection: correlation with inflammatory cytokines. Clin Chim Acta 2015 Feb 20;414:23-8.See comment in PubMed Commons below
12. Alstrup M et al. Soluble Urokinase Plasminogen Activator Receptor (suPAR) as an Added Predictor to Existing Preoperative Risk Assessments. World J Surg. 2019 43(3):780-790
13. Meyer J et al..suPAR is associated with risk of future acute surgery and postoperative mortality in acutely admitted medical patients. Scand J Trauma Resusc Emerg Med. 2018 Feb 1;26(1):11.

Authors:

Line Jee Hartmann Rasmussen

Andreas Sandø

Thomas Huneck Haupt

Jesper Eugen-Olsen

Kasper Karmark Iversen

Martin Schultz

Updated by Ditte Bjerre and Jesper Eugen-Olsen - June 2021

Have you considered your patient's prognosis?

suPAR level and mortality risk

Patients below the age of 70:

suPAR (ng/mL)	30 days	90 days
All (n=5925)	1.4%	2.5%
0-3 (n=3852)	0.2%	0.5%
3-6 (n=1661)	1.7%	3.4%
6-9 (n=287)	7.3%	11.1%
>9 (n=169)	16.6%	23.1%

Patients above the age of 70:

suPAR (ng/mL)	30 days	90 days
All (n=3666)	8.8%	15.3%
0-3 (n=750)	2.3%	3.5%
3-6 (n=1970)	5.3%	10.9%
6-9 (n=567)	16.6%	28.1%
>9 (n=379)	27.7%	43.0%

Source: The emergency departments at Hvidovre Hospital and Hillerød Hospital, Denmark. n=9591.

P-[suPAR]

Soluble urokinase plasminogen activator receptor
Unit: ng/mL   Interval: 0.1-16.0

Analysis time: 20 min; the result is available in
                    laboratory systems within 2 h.

Interpretation:

Elevated values are observed in pathological conditions and
correlate with the patient's mortality risk.

• **Highly elevated** values (>9) are observed in patients with
multiple chronic diseases and/or serious and life-threatening
conditions like severe sepsis or seriously impaired organ function.
Mortality risk is highly increased.

• **Moderately elevated** values (about 4-9) are, for example,
observed in the following conditions:
Infections, cancer, COPD, cardiovascular diseases, dementia,
diabetes, hepatic and renal diseases.
Mortality risk and readmission risk are increased.

• **Low values** (<3) indicate a good prognosis.

Comments:
• The suPAR level should be considered in relation to medical
history, clinical findings, and other paraclinical findings.

• If the suPAR level is elevated for no obvious reason, further
investigation for an unacknowledged disease may be considered.

• A low suPAR level indicates a low mortality risk and a low risk of
critical illness and may support a decision to discharge the patient.

How sick is your patient?

suPAR level

12+

HIGH RISK
Significantly increased mortality risk
Critical illness, organ failure
Severe sepsis, septic shock
Multiple chronic diseases

9

MODERATE RISK
Increased mortality risk
Prolonged hospital stays
Increased readmission risk

6 Infections and acute illness

Chronic diseases, e.g. COPD, diabetes,
cardiovascular diseases, dementia, peptic ulcer,
cancer, hepatic diseases, renal diseases

3

LOW RISK
Low mortality risk
Low readmission risk
No or well-treated comorbidities
Healthy individuals

0